文献速递鼻科小儿耳鼻咽喉

白藜芦醇与伊伐卡托对G551D CFTR通道的叠加增效作用:对囊性纤维化鼻窦疾病的意义

Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
PubMed 文献 · Int Forum Allergy Rhinol · 2018-08-27

本研究探讨白藜芦醇与伊伐卡托联合是否较单药更改善G551D CFTR介导的氯离子分泌。在转染G551D CFTR的Fisher大鼠甲状腺细胞和人鼻窦上皮细胞中,联合用药显著增加氯离子转运,提示白藜芦醇可能增强伊伐卡托疗效并改善囊性纤维化相关鼻窦炎。

要点

  • 白藜芦醇与伊伐卡托联合在G551D CFTR细胞中产生叠加性氯离子分泌增加。
  • 联合用药在G551D人鼻窦上皮细胞中同样显著优于单药。
  • 结果提示白藜芦醇可能增强伊伐卡托对囊性纤维化鼻窦疾病的疗效。

核心结论

  • 白藜芦醇与伊伐卡托对G551D CFTR介导的氯离子分泌具有叠加改善作用,提示白藜芦醇可能增强伊伐卡托治疗并改善囊性纤维化相关鼻窦炎。

研究设计与样本

  • 研究在转染G551D CFTR的Fisher大鼠甲状腺细胞(FRT)和含CFTR G551D突变的人鼻窦上皮细胞(HSNE)中进行,采用Ussing室药理学调控跨上皮离子转运,并在G551D FRT细胞中用全细胞膜片钳进一步评估。

主要发现

  • 在G551D FRT细胞中,白藜芦醇(100 μM)与伊伐卡托(10 μM)联合使短路电流变化(δISC)达4.97 ± 0.57 μA/cm2,显著高于伊伐卡托单药(0.74 ± 0.12)、白藜芦醇单药(2.96 ± 0.52)和DMSO对照(0.74 ± 0.12),p < 0.001。
  • 最大氯离子分泌(20 μM forskolin)在联合用药下也显著增强(p < 0.0001)。
  • 在G551D HSNE中,联合用药的δISC为4.48 ± 0.39,显著高于伊伐卡托(1.05 ± 0.11)、白藜芦醇(0.84 ± 0.3)和对照(0.0 ± 0.02),p < 0.001。
  • 全细胞膜片钳在G551D FRT细胞中显示,联合用药电流为-2535 ± 179.3 pA,显著大于伊伐卡托(-1408.9 ± 101.3 pA)和白藜芦醇(-766.2 ± 71.2 pA),p < 0.0001。

临床怎么用

  • 对于携带G551D突变的囊性纤维化患者,白藜芦醇可能作为伊伐卡托的辅助增效剂,但需进一步临床研究验证。

局限性

  • 研究仅基于细胞模型(FRT和HSNE),尚未在人体或动物模型中验证联合治疗的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in defective Cl- transport and cause chronic bacterial infections in the upper and lower airways of cystic fibrosis (CF) patients. Ivacaftor is a CFTR potentiator that improves Cl- transport in CF patients with at least 1 copy of the G551D mutation. Resveratrol is also a potent CFTR potentiator that increases determinants of mucociliary transport. The objective of this study is to determine whether resveratrol and ivacaftor improve Cl- secretion in G551D CFTR over either agent alone. METHODS: Fisher rat thyroid cells (FRT) transfected with G551D CFTR and human sinonasal epithelial cells (HSNE) containing the CFTR G551D mutation were subjected to pharmacologic manipulation of transepithelial ion transport in Ussing chambers. Activity was further evaluated using whole-cell patch clamp methods in G551D FRT cells. RESULTS: In G551D FRT cells, resveratrol (100 μM) and ivacaftor (10 μM) significantly increased Cl- transport (change in short-circuit current, δISC = μA/cm2 ) compared with single-agent and dimethylsulfoxide vehicle controls (resveratrol + ivacaftor 4.97 ± 0.57 vs ivacaftor 0.74 ± 0.12 vs resveratrol 2.96 ± 0.52 vs control 0.74 ± 0.12; p < 0.001). Maximal Cl- secretion (20 μM forskolin) was also significantly enhanced (p < 0.0001). Activity was confirmed in G551D HSNE (resveratrol + ivacaftor 4.48 ± 0.39 vs ivacaftor 1.05 ± 0.11 vs. resveratrol 0.84 ± 0.3 vs control, 0.0 ± 0.02; p < 0.001), and whole-cell patch clamp analysis in G551D FRT cells (resveratrol + ivacaftor -2535 ± 179.3 pA vs ivacaftor -1408.9 ± 101.3 pA vs resveratrol; -766.2 ± 71.2 pA; p < 0.0001). CONCLUSION: Additive improvement in G551D CFTR-mediated Cl- secretion suggests that resveratrol could enhance ivacaftor therapy in these patients and improve CF-related rhinosinusitis.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Cho DY, Zhang S, Lazrak A, et al. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease. Int Forum Allergy Rhinol. 2018. PMID: 30152192. doi:10.1002/alr.22202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。